We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+54.14%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.52B
AUM Growth
+$24M
(+1.6%)
Cap. Flow
-$83.5M
Cap. Flow
% of AUM
-5.5%
Top 10 Holdings %
Top 10 Hldgs %
56.06%
Holding
84
New
11
Increased
10
Reduced
18
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$39.4M |
| 2 |
BridgeBio Pharma
BBIO
|
+$37.2M |
| 3 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$31M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$28.6M |
| 5 |
Pliant Therapeutics
PLRX
|
+$18.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$50.1M |
| 2 |
Revolution Medicines
RVMD
|
+$45.1M |
| 3 |
Altimmune
ALT
|
+$42.8M |
| 4 |
VTYX
Ventyx Biosciences
VTYX
|
+$35.4M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.97% |
| 2 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $178M | 11.7% |
1,655,000
-435,000
| -21% | -$50.1M |
|
2
MoonLake Immunotherapeutics
MLTX
$1.56B
| $147M | 9.71% |
6,892,101
+827,100
| +14% | +$13.9M |
|
3
Biomea Fusion
BMEA
$88.2M
| $111M | 7.29% |
3,570,872
+400,000
| +13% | +$4.97M |
|
|
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
| $89.7M | 5.91% |
1,360,000
-216,872
| -14% | -$12.5M |
|
|
AMAM
5
DELISTED
Ambrx Biopharma Inc
AMAM
| $75.8M | 4.99% |
8,500,000
+6,163,611
| +264% | +$31M |
|
|
6
BridgeBio Pharma
BBIO
$16.4B
| $75.6M | 4.98% |
4,557,414
+3,188,235
| +233% | +$37.2M |
|
|
ACLX
7
DELISTED
Arcellx
ACLX
| $49.3M | 3.25% |
1,600,000
-475,000
| -23% | -$14.4M |
|
|
ETNB
8
DELISTED
89bio
ETNB
| $42.6M | 2.81% |
2,800,000
+250,000
| +10% | +$3.26M |
|
|
9
Enliven Therapeutics
ELVN
$3.78B
| $42.4M | 2.79% |
+1,936,133
| New | +$39.4M |
|
|
RNAM
10
DELISTED
Avidity Biosciences
RNAM
| $40.1M | 2.64% |
2,612,115
-150,000
| -5% | -$3.3M |
|
|
11
Protagonist Therapeutics
PTGX
$8.55B
| $39.1M | 2.58% |
+1,700,000
| New | +$28.6M |
|
|
12
Pliant Therapeutics
PLRX
$65M
| $38.4M | 2.53% |
1,444,000
+661,212
| +84% | +$18.8M |
|
13
Erasca
ERAS
$6.15B
| $32.5M | 2.14% |
10,813,246
| – | – |
|
|
JBIO
14
Jade Biosciences
JBIO
$1.18B
| $31.5M | 2.07% |
44,620
-11,298
| -20% | -$9.37M |
|
15
Design Therapeutics
DSGN
$751M
| $29.7M | 1.96% |
5,150,000
| – | – |
|
|
RAIN
16
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $26M | 1.71% |
2,978,660
| – | – |
|
17
Immuneering
IMRX
$262M
| $23.2M | 1.53% |
2,386,181
+100,000
| +4% | +$568K |
|
18
Monte Rosa Therapeutics
GLUE
$1.82B
| $22.5M | 1.48% |
2,893,717
| – | – |
|
19
Viridian Therapeutics
VRDN
$2.2B
| $21.6M | 1.42% |
850,000
-250,000
| -23% | -$8.02M |
|
|
VECT
20
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $21.6M | 1.42% |
2,536,617
| – | – |
|
21
Edgewise Therapeutics
EWTX
$4.28B
| $19.7M | 1.29% |
2,946,887
| – | – |
|
22
Axsome Therapeutics
AXSM
$11.7B
| $18.5M | 1.22% |
300,000
-25,000
| -8% | -$1.64M |
|
23
Tarsus Pharmaceuticals
TARS
$2.55B
| $17.9M | 1.18% |
1,421,422
-315,000
| -18% | -$4.61M |
|
|
AXNX
24
DELISTED
Axonics, Inc. Common Stock
AXNX
| $17.6M | 1.16% |
322,240
| – | – |
|
25
Viking Therapeutics
VKTX
$3.88B
| $17.5M | 1.15% |
1,050,000
+350,000
| +50% | +$3.62M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, Cormorant Asset Management held 84 positions worth $1.52B, up 1.6% from $1.49B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Cormorant Asset Management withdrew a net $83.5M in Q1 2023, closing 12 positions and reducing 18 holdings. Its most notable exit was Revolution Medicines, an estimated $45.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Enliven Therapeutics worth $42.4M.
- Cormorant Asset Management's largest Q1 2023 buy was Enliven Therapeutics: 1,936,133 shares worth $42.4M.
- Cormorant Asset Management added most to BridgeBio Pharma in Q1 2023, an estimated $37.2M increase.
- Cormorant Asset Management's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $50.1M.
- Cormorant Asset Management fully exited Revolution Medicines in Q1 2023, selling an estimated $45.1M.
- Cormorant Asset Management's ten largest holdings make up 56% of its $1.52B portfolio in Q1 2023.
- Cormorant Asset Management opened 11 new positions and closed 12 in Q1 2023.
- Cormorant Asset Management's portfolio value rose 1.6% quarter-over-quarter to $1.52B.
Based on Cormorant Asset Management's 13F filing for Q1 2023, filed 15 May 2023.